- Price
- $4.52
- Day
- +2.96%
- Mkt Cap
- $257.34M
- 52W Range
- $0.75 – $5.69
- Volume
- 215.0K
- Beta
- 0.95
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read full article
ADAR1 Capital Management LLC purchased a new position in shares of Prelude Therapeutics Incorporated (NASDAQ: PRLD) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 152,825 shares of the company's stock, valued at approximately $523,000. ADAR1 Capital Management
Read full article
Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read full article